Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Real-Life Study of Long-Term Efficacy,Safety and Correlation Between Clinical Effectiveness and Subjective Perception of Disease

Chiricozzi A , Ortoncelli M , Schena D , et al. Long-term effectiveness and safety of Upadacitinib for atopic dermatitis in a real-world setting: An interim analysis through 48 weeks of observation. Am J Clin Dermatol., 2023; 24(6):953–961; doi: 10.1007/s40257-023-00798-0

Guttman-Yassky E , Teixeira HD , Simpson EL , et al. Once-daily Upadacitinib versus Placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet., 2021; 397(10290):2151–2168; doi: 10.1016/S0140-6736(21)00588-2

Simpson EL , Papp KA , Blauvelt A , et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the measure Up 1 and measure up 2 randomized clinical trials. JAMA Dermatol., 2022; 158(4):404–413; doi: 10.1001/jamadermatol.2022.0029

Silverberg JI , Gooderham MJ , Katoh N , et al. 403 Achievement of minimal disease activity is associated with improvements in symptoms, quality of life and treatment satisfaction in patients with atopic dermatitis. British Journal of Dermatology., 2023; 188(Suppl 3):ljad162.026; doi: 10.1093/bjd/ljad162.026

Reich K , de Bruin-Weller MS , Deleuran M , et al. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials. Journal of the European Academy of Dermatology and Venereology., 2023; 37(8):1634–1641; doi: 10.1111/jdv.18995